TB-500 vs TB-500 + BPC-157
TB-500 is the synthetic acetylated fragment Ac-LKKTETQ, marketed as an analogue of thymosin beta-4, a 43-amino-acid endogenous actin-sequestering peptide. TB-500 + BPC-157 is the same fragment supplied together with BPC-157, a synthetic pentadecapeptide corresponding to a fragment of a protein found in gastric juice. The pairing is sold on the premise that the two peptides work better together than either does alone, which makes this one of the few comparisons in the category where the decisive experiment actually exists. A 2026 rat Achilles tendon study randomised animals to an untreated control, BPC-157 alone, TB-500 alone and the two combined, and reported that combined treatment conferred no additional benefit over either agent given alone. A 2021 retrospective chart review is the only human record in which anyone received the two peptides together. Everything else that names both is review literature.
They have been compared directly.
Biçer and colleagues randomised 32 male Sprague-Dawley rats after standardised Achilles tendon transection and repair into four groups of eight: untreated control, BPC-157 alone, TB-500 alone, and the two peptides combined, with intraperitoneal treatment for four weeks. The TB-500 arm was the only treated arm to reach statistical significance for maximum load to failure against controls, and it also showed significantly lower total Bonar and Movin histopathological scores. The combination arm showed significantly lower total Movin scores than controls but, as the authors stated explicitly, conferred no additional benefit compared with either peptide given alone; they offered convergence on shared downstream pathways as a possible explanation and noted that the hypothesis required further experimental confirmation. In humans the only record is a retrospective chart review at a single private clinic, in which twelve of sixteen contactable knee-pain patients had received BPC 157 alone and four had received it combined with thymosin beta-4, with self-rated pain as the only outcome, no control group and no validated instruments. Seventeen further publications name both peptides without administering either.
The 19 studies that tested both
- 01Animal in vivo2026
Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study
Biçer O, et al. · Jt Dis Relat Surg · rat Achilles tendon transection and repair; 32 male Sprague-Dawley rats in 4 groups of 8 (control, BPC-157, TB-500, and a dedicated BPC-157 plus TB-500 combination arm), intraperitoneal administration for 4 weeks, with biomechanical, histopathological, histochemical and immunohistochemical analysis
This is the only published experiment that tested the combination against each peptide alone. Maximum load to failure was higher in both single-agent groups than in controls but reached statistical significance only for TB-500 (p < 0.05), which also showed significantly lower total Bonar (p = 0.016) and Movin (p = 0.017) scores. The combination arm showed significantly lower total Movin scores than controls, and the authors stated that combined treatment did not confer additional benefit compared with either agent alone, hypothesising convergence on shared downstream pathways. The work was described as exploratory and preliminary.
- 02Human clinical2021
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
Lee E, Padgett B · Altern Ther Health Med · retrospective chart review at a single private clinic covering 2019 to 2020; 17 patients given intra-articular BPC 157 alone or combined with thymosin beta-4, with telephone follow-up obtained in 16
This is the only human record in which anyone received the two peptides together. Twelve of the sixteen contactable patients had received BPC 157 alone, of whom eleven reported significant improvement in knee pain; the remaining four received BPC 157 combined with thymosin beta-4, of whom three reported significant improvement and one reported none. No validated outcome instrument was used, there was no control group, and the four-patient combination subgroup was too small to support any inference about combination effect.
- 03Systematic review2026
Peptide Supplements and Their Therapeutic Applications in Sports Medicine
Tewari K, et al. · Am J Sports Med · PRISMA-guided scoping review of six peptides, including BPC-157 and TB-500, against musculoskeletal tissue outcomes
The review appraised both peptides as separate entries and identified no trial of the two given together. It reported that around two thirds of the identified literature used preclinical animal models and that human clinical studies were limited to a handful of investigations.
- 04Review2026
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Mendias CL, Awan TM · Sports Med · narrative review of approved and unapproved peptides marketed direct to patients, covering both BPC-157 and thymosin beta-4 or TB-500
The review discussed both peptides among unapproved musculoskeletal agents and identified no combination evidence. It reported favourable tissue-repair outcomes in animal models alongside scarce human safety data, and discussed placebo effects and social media amplification as contributors to perceived efficacy.
- 05Review2026
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Mayfield CK, et al. · Am J Sports Med · narrative review of injectable peptide therapies including BPC-157, thymosin beta-4 and TB-500
The review covered both peptides and administered neither. It reported that BPC-157 showed potential in tendon and muscle repair that was largely unvalidated in human trials, noted the single human knee case series and its methodological limitations, and stated that thymosin beta-4 and TB-500 promoted angiogenesis and tissue repair in preclinical models while human orthopaedic data were lacking.
- 06Review2026
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Rahman OF, Lee SJ, Seeds WA · J Am Acad Orthop Surg Glob Res Rev · narrative review of therapeutic peptides in orthopaedic practice, tabulating wound-healing peptides and their molecular pathways
The review grouped BPC-157, TB-500 and GHK-Cu together as wound-healing peptides acting on angiogenesis, integrin-mediated extracellular matrix remodelling and fibroblast activation, and tabulated separate pathway sets for each. It described TB-500 as a fragment derived from thymosin beta-4 whose reported anti-inflammatory and proangiogenic effects mirror those of BPC-157, and recorded a current lack of clinical trials.
- 07Review2026
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Mavrych V, Shypilova I, Bolgova O · Front Aging · narrative review with systematic searches of PubMed, Scopus and regulatory databases from inception to January 2026, covering nine named peptides including BPC-157 and TB-500
The review named both peptides as its tissue-repair pair and assessed them separately rather than as a combination. It described TB-500 as the seven-amino-acid synthetic thymosin beta-4 fragment Ac-LKKTETQ acting through actin regulation and anti-inflammatory mechanisms, recorded that human evidence for TB-500 was limited to a single phase 1 safety and pharmacokinetics trial, noted that the highest available human evidence for BPC-157 consisted of small pilot studies, and listed a theoretical tumour angiogenesis concern for TB-500 and unknown systemic safety for BPC-157.
- 08Review2026
Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management
Luansritisakul C, et al. · Curr Pain Headache Rep · narrative review of regenerative peptides relevant to chronic pain management, covering BPC-157, thymosin beta-4 and TB-500 among others
The review listed BPC-157, thymosin beta-4 and TB-500 as distinct entries and reviewed the proposed mechanisms, clinical applications, preclinical and clinical evidence, safety profiles and regulatory status of each. It concluded that evidence for regenerative peptides in chronic pain remained limited and that most of these therapies were unapproved by the US Food and Drug Administration.
- 09Review2026
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Renke G, Chinellato L · Int J Mol Sci · narrative review of therapeutic peptides used in aesthetic, metabolic and endocrine practice, with BPC-157 and TB-500 among the explicit search terms and a summary table of molecular formulae and regulatory status
The review treated BPC-157 and TB-500 as separate compounds and did not discuss the two given together. It tabulated each with its molecular formula and regulatory position, recording BPC-157 on a compounding bulks list and covering thymosin beta-4 in the same table, and made no claim of combination benefit.
- 10Review2026
Current State of Orthobiologics in Treatment of Knee Osteoarthritis-Future Directions
Lee W, et al. · Int J Mol Sci · narrative review of orthobiologics for knee osteoarthritis, including a summary of the 2021 intra-articular peptide chart review
This review is one of the few publications to engage the combination directly, by summarising the 2021 chart review. It recorded that Lee and Padgett evaluated BPC-157 and the combination therapy of BPC-157 with thymosin beta-4 in 16 patients with knee pain, that 14 of 16 reported significant pain relief with either BPC-157 or the combination from six months to one year after injection, and that the absence of human clinical trials left both efficacy and safety uncertain.
- 11Review2026
From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management
Yuan C, et al. · Int J Mol Sci · narrative review centred on BPC-157, with a section recounting the human intra-articular knee series in which some patients received thymosin beta-4 alongside it
The review described thymosin beta-4 as a naturally occurring protein fragment important for tissue repair, regeneration and wound healing, and recorded that four patients in the retrospective chart review received BPC-157 combined with it, of whom three reported significant improvement and one reported no pain relief. It noted the small sample size and the varied follow-up inherent to a retrospective chart review.
- 12Review2026
Peptide-Based Approaches for Pain Relief and Healing in Wounds
Kołodyńska K, Kamysz W, Kleczkowska P · Int J Mol Sci · narrative review of peptides in wound healing and analgesia, covering BPC-157 and thymosin beta-4
The review reported that BPC-157 improved granulation tissue formation, re-epithelialisation and dermal remodelling in treated animals but did not show an analgesic effect in an incisional model of acute inflammatory pain, and that clinical reports described improvement in a majority of knee-pain patients after intra-articular administration both as monotherapy and in combination with thymosin beta-4. It stated separately that data on thymosin beta-4 and pain modulation were currently lacking.
- 13Review2026
Peptides for Targeting Chondrogenic Induction and Cartilage Regeneration in Osteoarthritis
Liao HJ, Chen HT, Chang CH · Cartilage · narrative review of peptides for chondrogenic induction and cartilage regeneration, with a tabulated evidence summary listing BPC-157 alone, BPC-157 combined with thymosin beta-4, and thymosin beta-4 in chondrocyte culture
The review identified BPC-157 and thymosin beta-4, which it also names as TB 500, among the peptides recognised for bone and joint applications. Its evidence table listed BPC-157 alone and the BPC-157 plus thymosin beta-4 combination against the 16-patient human knee series, and listed thymosin beta-4 separately against in vitro treatment of primary articular chondrocytes.
- 14Review2026
Emerging Biologics in Lumbar Disc Degeneration: PRP, Stem Cell Therapy, and Pharmacotherapy in Mobility Restoration and Rehabilitation
Aabedi A, Agrawal DK · J Spine Res Surg · narrative review of biologics for lumbar disc degeneration, with a peptide section covering BPC-157, thymosin beta-4 and GHK-Cu
The review grouped both peptides as molecular candidates for musculoskeletal and intervertebral disc degeneration and made no claim about combining them. It attributed BPC-157 effects to nitric oxide pathway regulation and anti-inflammatory activity in rodent models of tendon, ligament, muscle and bone repair, and described thymosin beta-4 as facilitating cell migration, angiogenesis and tissue restoration. It stated that human clinical data remained absent and that BPC-157 lacked regulatory authorisation.
- 15Review2026
Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation
Mazza AD · Integr Med (Encinitas) · narrative review of peptide interventions relevant to thyroid biology, summarising selected peptides including thymosin alpha-1, thymosin beta-4 and BPC-157
The review examined the mechanistic rationale for peptide interventions in thyroid biology and summarised the state of evidence for each selected peptide separately, naming thymosin beta-4 and BPC-157 among them. The domain is unrelated to musculoskeletal repair and no combination of the two was discussed or tested.
- 16Review2024
Discovery of bioactive peptides as therapeutic agents for skin wound repair
Md Fadilah NI, et al. · J Tissue Eng · narrative review of bioactive peptides for skin wound repair, with a tabulated catalogue of peptide sources and sequences
The review catalogued both peptides as separate entries in its source-and-sequence table, listing thymosin beta-4 with its full 43-residue sequence and origin in biological fluids, and BPC-157 with the sequence GEPPPGKPADDAGLV and its origin in human gastric juice. It reported no work in which the two were combined.
- 17In vitro2025
Illegal and falsified medicines self-administrated in not approved post-cycle therapy after the cessation of anabolic-androgenic steroids - qualitative analysis
Blazewicz A, et al. · Front Chem · qualitative chromatographic and spectrometric analysis of seized and self-administered illegal or falsified products, screened against declared and undeclared active ingredients
The analysis grouped BPC-157 and thymosin beta-4 with its derivatives among the prohibited substances encountered in the sampled products, classifying BPC-157 under the non-approved substances category and thymosin beta-4 under growth factors and growth factor modulators. In three samples declared as containing anabolic steroids or BPC-157, undeclared raloxifene was identified alongside other undeclared ingredients. The work characterised product content rather than biological effect.
- 18Review2025
Annual Banned-Substance Review 17th Edition-Analytical Approaches in Human Sports Drug Testing 2023/2024
Thevis M, Kuuranne T, Geyer H · Drug Test Anal · annual review of analytical approaches in human sports drug testing, tabulating the prohibited list by class and summarising new detection methods
The review placed the two peptides in different prohibited categories: BPC-157 among non-approved substances in class S0, and thymosin beta-4 and its derivatives, explicitly including TB-500, among growth factors in class S2. It also summarised in vitro metabolism work on BPC-157 using a stable isotope-labelled analogue to identify metabolites suitable as detection targets. It is a detection review, not an efficacy study.
- 19Review2026
Effects of Supplementation in Masters Athletes and Older Adults: A Narrative Review
Nguyen C, et al. · Curr Sports Med Rep · narrative review of supplements used by Masters athletes and adults over 55, covering protein, caffeine, creatine, beta-alanine, nitrates and peptides
The review examined body protection compound-157 and thymosin beta 4 and 500 among the peptide supplements considered for performance and musculoskeletal health in older athletes. It assessed the peptides as individual supplements and reported no evidence relating to their use in combination.
Side by side.
| TB-500 | TB-500 + BPC-157 | |
|---|---|---|
| Evidence maturity | Early clinical | Preclinical only |
| Studies cited here | 15 | 8 |
| Published 2023 or later | 8 | 5 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | One peptide: the acetylated seven-residue fragment Ac-LKKTETQ, sold as an analogue of thymosin beta-4, a 43-amino-acid endogenous actin-sequestering peptide that is widely expressed in human tissue. | Two unrelated peptides in one vial: the same Ac-LKKTETQ fragment plus BPC-157, a synthetic 15-amino-acid peptide, GEPPPGKPADDAGLV, corresponding to a fragment of a protein found in gastric juice and with no confirmed endogenous circulating counterpart. |
| Mechanism as described in the literature | Full-length thymosin beta-4 sequesters G-actin and promotes cell migration, with published biology covering angiogenesis, epicardial activation in cardiac repair, anti-fibrotic activity and inflammation resolution. The short fragment itself has very little independent pharmacology. | Adds the BPC-157 mechanism, described in rodent work as angiogenesis associated with VEGFR2 signalling and modulation of the nitric oxide system. Orthopaedic reviews describe the two mechanisms as mirroring each other rather than complementing each other, and the one experiment that tested them together hypothesised convergence on shared downstream pathways. |
| Size of the evidence base | Substantial for full-length thymosin beta-4, spanning cardiac, corneal, dermal, pulmonary and renal models plus completed human trials, though the marketed fragment appears in only a handful of papers, principally an analytical study quantifying it and its metabolites. | Two publications administered the two peptides together: one four-week rat tendon experiment and one uncontrolled human chart review. Every other publication naming both is a review or an analytical or anti-doping paper. |
| Best-characterised finding | In the rat Achilles study the TB-500 arm was the only treated arm to reach statistical significance for maximum load to failure, and it showed the lowest histopathological scores. Separately, full-length thymosin beta-4 increased re-epithelialisation by 42 percent at four days in the foundational rat dermal wound model. | The combination arm of the same rat study showed significantly lower total Movin scores than untreated controls but no additional benefit over either peptide given alone. That is the strongest published finding for the pairing, and it is a null result on the question the pairing is sold to answer. |
| Human data | Randomised, double-blind, placebo-controlled trials of thymosin beta-4 in healthy volunteers, severe dry eye and chronic venous ulcers, plus a 2025 report covering mice and patients with ST-segment elevation myocardial infarction. None examined tendon, ligament or muscle injury, and none used the marketed fragment. | One retrospective chart review at a single private clinic, in which four of sixteen contactable patients had received BPC 157 combined with thymosin beta-4. There was no control group, no validated outcome instrument and no randomisation, and the combination subgroup was four patients. |
| Demonstrated synergy | Not a question the single-agent literature addresses, since it tests one compound at a time. | None demonstrated. The only controlled test of the pairing reported that combining the peptides conferred no additional benefit over either alone, and no review located since has identified a combination trial in any tissue. |
| Regulatory and anti-doping status | No approved product for musculoskeletal recovery in any jurisdiction. The annual banned-substance reviews list thymosin beta-4 and its derivatives, explicitly including TB-500, among prohibited growth factors, and several recent publications are detection methods rather than efficacy studies. | Prohibited on two separate grounds, since BPC-157 is listed among non-approved substances in class S0 while thymosin beta-4 derivatives sit among growth factors in class S2. A 2025 analysis of illegal and falsified products found undeclared ingredients in samples declared as containing BPC-157. |
| Basis of most marketing claims | Extrapolation from the full-length thymosin beta-4 literature to a seven-residue fragment whose equivalence to the parent peptide is assumed rather than demonstrated, and from unrelated indications to tendon, ligament and muscle repair. | An assertion of synergy. The only experiment designed to test it found none, and the only human record of the pairing is four patients in an uncontrolled chart review. |
And what it does not.
This is one of the rare comparisons in the category where the decisive experiment has been run. A 2026 rat Achilles tendon study included a dedicated combination arm alongside TB-500 alone, BPC-157 alone and an untreated control, and reported that combining the peptides conferred no additional benefit over either agent given alone. TB-500 alone was the only arm to reach statistical significance for maximum load to failure. Those results describe one tissue, one species, one time point and eight animals per arm, and the authors called the work exploratory and preliminary, so they do not settle the question for humans or for other tissues. The human record for the pairing is four patients within an uncontrolled retrospective chart review, which used self-rated pain and no validated instrument. Around seventeen further publications name both peptides, but all are reviews, analytical papers or anti-doping documents, and none reports a combination trial. On the published evidence, the premise that the blend outperforms the single peptide is unsupported, and the only direct test of it was negative.
Common questions.
- Has the blend ever been tested against TB-500 on its own?
Once. A 2026 rat Achilles tendon study randomised 32 animals into four groups of eight: untreated control, BPC-157 alone, TB-500 alone, and the two peptides combined, with treatment for four weeks. The authors reported that combined treatment conferred no additional benefit compared with either agent alone. The TB-500 arm was the only treated arm to reach statistical significance for maximum load to failure and also showed the lowest total Bonar and Movin scores. That single exploratory rodent experiment is the whole of the direct comparison.
- Why would combining two repair peptides fail to add anything?
The authors of the rat study offered convergence on shared downstream pathways as a possible explanation, and stated that the hypothesis required further experimental confirmation. Orthopaedic reviews describe the two mechanisms in similar terms, with one primer noting that the anti-inflammatory and proangiogenic effects attributed to TB-500 mirror those attributed to BPC-157. If two agents push on the same endpoint through overlapping routes, adding the second may not move that endpoint further. Nothing in the published record confirms that account.
- What did the human combination data actually consist of?
A retrospective chart review at a single private clinic covering 2019 to 2020. Of the sixteen patients reached by telephone, twelve had received intra-articular BPC 157 alone and four had received it combined with thymosin beta-4. Eleven of the twelve monotherapy patients and three of the four combination patients reported significant improvement. There was no control group, no randomisation and no validated outcome measure, and the authors recorded that no specific tools were used to assess function, quality of life or stiffness.
- Is the blend easier to justify because both peptides are individually studied?
Component-level evidence does not transfer to a mixture. The reviews that name both peptides appraise them separately, and the scoping review in a sports medicine journal found roughly two thirds of the identified literature to be preclinical animal work with only a handful of human studies. No pharmacokinetic, stability or interaction study of the two peptides supplied together has been published, and neither peptide has controlled human evidence for tendon, ligament or muscle injury on its own.
- How do anti-doping authorities treat the single peptide and the blend?
Differently, and that difference carries over to the blend. The annual banned-substance reviews list thymosin beta-4 and its derivatives, explicitly including TB-500, among prohibited growth factors, while BPC-157 appears among non-approved substances in a separate category. A product containing both therefore falls under two prohibited classes at once. A 2025 qualitative analysis of illegal and falsified products also found undeclared ingredients in samples declared as containing BPC-157.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.